Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Cash from Investing Activities (2016 - 2025)

Cardiff Oncology's Cash from Investing Activities history spans 15 years, with the latest figure at $10.7 million for Q4 2025.

  • For Q4 2025, Cash from Investing Activities rose 138.28% year-over-year to $10.7 million; the TTM value through Dec 2025 reached $1.3 million, down 90.22%, while the annual FY2025 figure was $1.3 million, 90.22% down from the prior year.
  • Cash from Investing Activities for Q4 2025 was $10.7 million at Cardiff Oncology, up from $10.2 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $18.4 million in Q1 2022 and bottomed at -$111.7 million in Q1 2021.
  • The 5-year median for Cash from Investing Activities is $6.1 million (2022), against an average of -$2.1 million.
  • The largest YoY upside for Cash from Investing Activities was 5326.62% in 2021 against a maximum downside of 15328.07% in 2021.
  • A 5-year view of Cash from Investing Activities shows it stood at -$8.8 million in 2021, then soared by 179.83% to $7.0 million in 2022, then surged by 93.18% to $13.6 million in 2023, then plummeted by 66.74% to $4.5 million in 2024, then surged by 138.28% to $10.7 million in 2025.
  • Per Business Quant, the three most recent readings for CRDF's Cash from Investing Activities are $10.7 million (Q4 2025), $10.2 million (Q3 2025), and -$5.0 million (Q2 2025).